Pharming Group N.V annual ebitda margin
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V EBITDA Margin Growth & History (PHAR)
Pharming Group N.V's ebitda margin was 8.98% for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 8.98% | +9.27 pp |
| 2024 | 2024-12-31 | −0.29% | −1.09 pp |
| 2023 | 2023-12-31 | 0.81% | −10.94 pp |
| 2022 | 2022-12-31 | 11.74% | +1.71 pp |
| 2021 | 2021-12-31 | 10.03% | −28.76 pp |
| 2020 | 2020-12-31 | 38.79% | +0.12 pp |
| 2019 | 2019-12-31 | 38.67% | — |
Pharming Group N.V quarterly ebitda margin
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 9.70% | −0.79 pp |
| Q1 2026 | 2026-03-31 | 1.46% | — |
| Q4 2025 | 2025-12-31 | 8.83% | — |
| Q3 2025 | 2025-09-30 | 24.08% | — |
| Q2 2025 | 2025-06-30 | 10.50% | — |
Pharming Group N.V ebitda margin trends
Over the last five fiscal years, Pharming Group N.V's ebitda margin decreased from 38.79% to 8.98%, a change of −29.81 percentage points. The latest reported quarter, Q2 2026, shows 9.70%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...